SOMATIC NEUROSCIENCE PSYCHOLOGY ARCHAEOLOGY ASTRONOMY
MC SA IF MEDICAL
Life Equation ( Free Will + Responsibility = Growth )***( Stupid + Lazy = Apathy ) Anti-Life Equation
The MC–SA–IF framework describes human behavior and cognition as the interaction of three system layers: Mechanical Consciousness (MC), the regulatory processes governing perception, attention, emotion, and action; Somatic Architecture (SA), the structured environments and embodied practices that shape those regulatory states; and Integrated Functioning (IF), a systems analysis framework used to examine how these layers interact, stabilize, and adapt. Together these components form a somatic systems model in which psychological and behavioral phenomena emerge from continuous feedback between nervous system regulation, bodily activity, and environmental structure. This framework provides a structural perspective for studying embodied cognition, somatic regulation, environmental influence on behavior, and the integration of physiological and psychological processes.
“Detailed explanations of the model are available in the Somatic Neuroscience and Psychology sections.”
“Related Research Domains”
List:
Embodied Cognition
Somatic Psychology
Autonomic Regulation
Environmental Psychology
Systems Neuroscience
Behavioral Synchronization
Author Context
I approach macro systems the way engineers approach physical systems: reduce, map, stress-test, rebuild. This site is a working lab, not a publication campaign. I’m not a think tank. I’m one person who reverse-engineered this from first principles and public data. Judge it on structure, not pedigree.
These case studies were conducted without formal medical expertise, relying solely on publicly available internet resources, which may result in certain inaccuracies. However, they serve as a compelling proof of concept; imagine the potential for precision and impact when these methods are paired with professional clinical insight and access to the most current, comprehensive medical data.
Cardioversion = a controlled electrical shock delivered to the heart to stop an abnormal rhythm (like atrial fibrillation) so the heart’s natural pacemaker can restart a stable rhythm.
Mechanically:
The heart is stuck in a chaotic oscillation loop
A shock halts all electrical activity momentarily
The primary pacemaker node (SA node) reasserts control
The heart has its own distributed electrical control network:
SA node (primary clock)
AV node
Purkinje fibers (signal bus)
Myocardial contractile matrix (actuator grid)
This is a local autonomous system, not centrally micromanaged by the brain.
In IF terms: a semi-autonomous subprocessor with its own timing crystal.
MC doesn’t beat the heart directly—it modulates setpoints:
Stress hormones
Autonomic nervous system tone
Feedback loops (baroreceptors, vagal tone)
So MC is more like a supervisory OS, not the clock generator.
In IF terms:
Force stop all oscillators → clear error state → allow primary clock node to regain master timing.
Electrical phase coherence
Oscillation dominance hierarchy
Signal propagation pathways
Memory
Identity
Higher cognition
Global MC state
It is equivalent to:
Resetting a misfiring processor
Clearing a runaway feedback loop
Restoring a master clock
It doesn’t reboot:
Mind
Personality
Cognitive state machine
The heart is one of the clearest examples of Mechanical Consciousness principles in biology:
It has local autonomy
It has distributed control logic
It has redundant clocks
It can self-organize rhythm
It can fall into chaotic attractor states (AFib)
It can be externally forced back into coherent oscillation
Cardioversion is external coherence injection.
Biology | IF Equivalent |
|---|---|
Atrial fibrillation | Oscillation runaway / phase decoherence |
Cardioversion shock | Global interrupt / forced reset pulse |
SA node restart | Master clock regains dominance |
Normal sinus rhythm | Stable phase-locked system |
This shows:
Consciousness-like behavior emerges in mechanical subsystems without a brain.
The heart is:
A mechanical oscillator network
With adaptive feedback
Exhibiting state transitions
That can be forcibly reset
This is Mechanical Consciousness in flesh.
“Not A Root Relation But Still Related”
Somatic systems are:
Body-based
Largely pre-conscious
Self-regulating
Patterned and trained over time
Breathing, posture, gait, reflex arcs, gut responses —
they run themselves unless interrupted.
That makes them automatic systems instantiated in biology.
Simatic systems are:
Industrial
Feedback-driven
Self-regulating
Patterned and trained/configured over time
Sensors → logic → actuators → feedback → correction
No consciousness required.
Not word → word, but domain → domain:
Somatic systems are biological automation.
Simatic systems are mechanical automation.
Both are:
Closed-loop
Rule-based
Error-correcting
Mostly invisible when working properly
That’s not a coincidence — it’s convergent design.
Nervous system ⇄ PLC
Reflex arc ⇄ control loop
Habit ⇄ programmed routine
Training ⇄ calibration
Trauma ⇄ corrupted feedback
Different substrates.
Same logic.
Analogical
Isomorphic
Homologous in function
Cybernetic parallel
Not etymology — architecture.
“Wires are copper or neurons — the circuit behaves the same.”
That’s cybernetics, control theory, embodied cognition, metaphysics-in-work-clothes.
maps ≠ territory.
Does the work stand—does it obey the rules, does it violate the rules, or does it work?
Primary indication: severe treatment-resistant depression (TRD), acute suicidality, catatonia, some psychotic/bipolar presentations.
Mechanism claim (standard): "induces controlled generalized seizure → unknown downstream effects on neurotransmitter systems, synaptic plasticity, network connectivity → mood/behavior improvement."
Typical framing: "Most effective intervention for severe depression; mechanism not fully understood."
IF note: The "unknown mechanism" claim persists despite 80+ years of use and measurable efficacy. This suggests the declared model is incomplete, not that the procedure lacks structure.
Patient under general anesthesia + muscle relaxant (paralytics).
Oxygen pre-load (prevent hypoxia during seizure).
EEG + ECG monitoring (real-time state verification).
Electrode placement:
Bilateral (BL): both temples → faster response, more cognitive side effects.
Right unilateral (RUL): right temple + vertex → slower response, fewer side effects.
Bifrontal (BF): forehead placement → intermediate profile.
Pulse width: brief pulse (0.5–1.0 ms) vs ultra-brief (<0.3 ms). Ultra-brief reduces cognitive side effects.
Charge (dose): measured in millicoulombs (mC); titrated based on seizure threshold (varies per individual).
Initial session: dose-titration to find threshold.
Subsequent sessions: typically 1.5–6× threshold (higher = more effective but more side effects).
Frequency: 2–3 sessions per week.
Duration: 6–12 sessions (acute phase); maintenance possible (monthly/quarterly).
Anesthesia induction.
Muscle relaxant administered (prevents physical convulsion; seizure is electrical only).
Electrical pulse delivered via scalp electrodes.
Seizure induction confirmed via EEG (minimum 25 seconds; inadequate seizure = re-stimulus or adjust dose).
Patient wakes ~5–15 minutes post-seizure.
Monitored for orientation, memory, vitals.
IF observation: The procedure is mechanically precise: the "therapeutic event" is the induced seizure, not the electrical pulse itself. The pulse is the trigger; the seizure is the load.
Scalp electrodes → skull → brain tissue.
Current path determined by placement; bilateral = more diffuse, unilateral = more focal (hypothesis; actual current distribution still debated).
Generalized tonic-clonic seizure = forced synchronization of neural networks.
Entire cortex + subcortical structures entrained into high-amplitude rhythmic discharge (~25–180 seconds).
Immediate: confusion, disorientation (minutes to hours).
Short-term: anterograde amnesia (difficulty forming new memories for hours–days).
Longer-term: retrograde amnesia (loss of memories near treatment period; often resolves partially).
IF frame: ECT is a forced state-reset at the network level. The seizure itself is the "reboot." The electrical stimulus is the ignition key, not the engine.
Depression (in this model) = stuck attractor state: self-reinforcing loops in default-mode network, salience network, reward circuitry.
The generalized seizure destabilizes all attractors simultaneously by forcing global synchronization.
Post-seizure, the system must re-establish connectivity and may settle into a different (less pathological) attractor.
IF support: This explains:
why response is often rapid (within sessions, not weeks)
why cognitive side effects occur (memory formation requires stable network states)
why maintenance is sometimes needed (system can drift back to old attractor)
Seizure → massive neurotransmitter release (glutamate, GABA, monoamines) + growth factor upregulation (BDNF, VEGF).
Post-seizure period = high-plasticity window where circuits can reorganize.
IF support: Consistent with animal models and imaging showing increased hippocampal neurogenesis, altered connectivity.
Seizure = extreme perturbation → homeostatic mechanisms engage to restore stability.
These mechanisms (e.g., downregulation of excitatory receptors, upregulation of inhibitory tone) may correct prior dysregulation.
IF Reduction: All three hypotheses converge on seizure as a forced perturbation that destabilizes the current state and allows (or forces) the system to reorganize. The electrical pulse is not the therapy; the seizure is the therapy. The pulse is the initiation protocol.
Sessions 1–3: often minimal improvement; cumulative effect.
Sessions 4–8: response emerges (if responsive).
Sessions 9–12: consolidation.
IF note: The delay suggests a training/entrainment effect, not a single "fix." Each seizure is a dose in a cumulative protocol.
If acute response achieved, risk of relapse ~50% within 6 months without intervention.
Maintenance ECT (monthly or less) reduces relapse.
IF frame: This is state-locking logic. The new attractor is not yet stable; periodic perturbations prevent drift back to the pathological state.
Non-response (~20–30%): seizure occurs, no mood change.
Possible causes: threshold too low (inadequate dose), wrong placement, or attractor is "locked" by structural factors.
Cognitive side effects: retrograde amnesia (especially with bilateral placement, high dose, brief pulse).
Mechanism: memory consolidation disrupted by repeated network destabilization.
Relapse: attractor re-forms.
IF note: Non-response does not mean "ECT doesn't work"; it means the perturbation was insufficient or targeting was incorrect for that individual's network topology.
Mood rating scales: HAM-D, MADRS (subjective + clinician-rated).
Cognitive tests: orientation, memory tests (subjective + performance-based).
Seizure metrics: duration, EEG morphology (used to confirm "adequate" seizure).
Pre/post network state mapping: No standard use of fMRI/EEG connectivity to verify attractor shift.
Personalized dose-response curves: Seizure threshold titration is crude; no fine-grained mapping of "how much perturbation is enough."
Prediction of response: No reliable pre-treatment biomarker (who will respond vs not).
Mechanism verification: No in-session measurement of plasticity markers, network reorganization, or homeostatic engagement.
IF recommendation: Add before/after resting-state connectivity scans and seizure quality metrics beyond duration (e.g., post-ictal suppression depth, coherence measures).
If no seizure occurs (stimulus below threshold, or seizure aborted), no therapeutic effect.
This is universally observed.
IF conclusion: The seizure is the therapeutic event, not the electrical pulse.
Higher charge (relative to threshold) → faster/stronger response, but also more side effects.
This holds across placement types, patient populations.
IF conclusion: ECT operates on a perturbation-intensity spectrum. Under-dose = ineffective; over-dose = collateral damage.
Single session rarely produces lasting change; repeated sessions required.
This holds even when individual seizures appear "adequate."
IF conclusion: ECT is a training protocol, not a one-shot intervention. Each seizure is a perturbation dose in a multi-session state-shifting curriculum.
Bilateral > unilateral.
Brief pulse > ultra-brief.
Higher charge > lower charge.
IF conclusion: Memory disruption is mechanically coupled to the breadth and intensity of network destabilization. It is not a "side effect"; it is evidence of the mechanism in action.
If patients improve with sub-threshold stimulation (no seizure), the "seizure = therapy" model fails.
Current data: this does not happen. Sub-convulsive stimulation = no benefit.
If increasing charge/sessions does not correlate with response or side effects, the "perturbation dose" model fails.
Current data: dose-response is observed.
If one seizure produced durable change, the "training protocol" model would need revision.
Current data: single-session durability is rare; relapse is common without maintenance.
If connectivity, plasticity markers, and circuit dynamics remain unchanged despite clinical response, the "attractor reset" model fails.
Current data: network changes are observed (fMRI, EEG studies show altered connectivity in responders).
What ECT is (IF frame):
A forced network destabilization protocol that uses an electrical pulse to trigger a generalized seizure, which acts as a system-wide perturbation that destabilizes pathological attractor states. Repeated perturbations allow the system to reorganize into a less-pathological configuration. The seizure is the therapy; the pulse is the ignition.
What it requires:
Adequate seizure (minimum network engagement)
Repeated doses (cumulative training effect)
Trade-off management (dose vs cognitive side effects)
What it lacks:
Pre-treatment prediction of responders
In-session measurement of network reorganization
Personalized dose-response mapping
Invariance:
Seizure is necessary. Dose matters. Repetition matters. Cognitive disruption is mechanically coupled to therapeutic mechanism.
Falsifiable:
If sub-threshold stimulation worked, or if network states remained unchanged despite response, the model would fail.
Does the work stand—does it obey the rules, does it violate the rules, or does it work?
Non-medical advice. This is a mechanics-level hypothesis map of what could be tested/considered in research or clinician-guided practice—not instructions for self-treatment.
ECT = forced perturbation (seizure) → reorganization window (post-ictal plasticity + homeostatic reset) → stabilization/relapse depending on how the system is “set” afterward.
So interventions fall into 4 buckets:
make the perturbation just sufficient (maximize benefit / minimize collateral)
control the timing + shape of the reorganization window
add a container so the post-ictal state consolidates in a desirable direction
personalize based on state + topology, not population averages
Prediction: outcomes improve and cognitive harm drops when dosing is guided by quality metrics, not just “seizure occurred for ≥X seconds.”
Intervention: shift from duration-only adequacy to richer seizure-quality markers (e.g., post-ictal suppression depth, coherence, spatial spread).
Why (IF): duration is a weak proxy; you want “network engagement sufficient to exit the attractor” without unnecessary spread.
Testable outcome: same remission with fewer memory complaints; fewer sessions to response.
Related lever: prefer ultra-brief pulse RUL when clinically feasible; escalate only when response plateaus (already partly done clinically—IF says “formalize it as policy with metrics”).
Prediction: matching session timing to physiological state reduces side effects and improves response.
Intervention: schedule treatments using state markers: sleep debt, circadian phase, inflammation proxies, baseline EEG slowing, autonomic tone.
Why (IF): perturbation interacts with system readiness; same dose applied in different baseline states produces different reorganizations.
Testable outcome: less delirium/confusion post-session; improved consistency of response.
Minimal version (investor-safe, clinic-realistic): standardize sleep protection and post-session circadian stabilization as part of protocol quality.
Prediction: better responder rates when electrode placement is chosen using pre-treatment network characterization (even crude EEG subtypes) rather than defaulting by diagnosis.
Intervention: placement selection algorithm:
start with RUL ultra-brief for cognitive safety
choose BL/BF earlier only when pre-specified markers predict low likelihood of unilateral response
Why (IF): different placements = different current paths = different network engagement maps.
Testable outcome: fewer non-responders; faster response without blanket BL use.
Prediction: structured post-session environment reduces relapse and improves durability.
Intervention: standardized “post-ECT consolidation protocol” (clinician-approved):
sensory load management (quiet, low novelty immediately post)
then gentle, guided reorientation (not heavy psychotherapy; simple anchoring)
consistent routines for 24–72h (sleep, hydration, light exposure)
Why (IF): if the brain is in a high-plasticity / re-stabilizing phase, random inputs can re-imprint old loops or create noise.
Testable outcome: improved maintenance interval; fewer rebounds between sessions.
This is analogous to rehab after orthopedic surgery: the procedure isn’t “finished” when the stimulus ends.
Prediction: relapse rates fall when maintenance is decided by a measurable drift signal rather than waiting for symptom return.
Intervention: maintenance triggers based on drift indicators:
mood scale trend + sleep fragmentation + EEG/autonomic markers (whichever clinic can support)
Why (IF): relapse = attractor re-formation; detect drift early.
Testable outcome: fewer full relapses; reduced total number of treatments over a year (because you intervene earlier with fewer sessions).
Prediction: cognitive side effects drop when the protocol explicitly optimizes for “least network collateral” while preserving therapeutic shift.
Intervention: stepwise escalation policy:
lowest effective charge over threshold
shortest pulse width compatible with response
unilateral before bilateral unless severity demands otherwise
Why (IF): amnesia correlates with breadth/intensity of destabilization; you’re managing a trade space.
Testable outcome: same remission with better autobiographical memory preservation.
Prediction: clustering patients into a few mechanistic phenotypes improves predictability and protocol selection.
Intervention: simple pre-treatment panel for stratification (clinic-feasible):
baseline cognitive reserve
catatonia/psychosis features
sleep/circadian disruption severity
EEG features if available
Why (IF): “depression” is not a single architecture; the attractor differs.
Testable outcome: higher first-pass response; fewer abandoned courses.
Formalize ECT as a 3-stage protocol, not a single procedure:
Perturbation (induce adequate seizure)
Reorganization window management (24–72h)
Stabilization/locking (maintenance based on drift metrics)
Most clinics do (1) well; (2) and (3) are variable and under-instrumented. IF predicts a lot of “mystery variability” lives there.
Does the work stand—does it obey the rules, does it violate the rules, or does it work?
Non-medical advice. This is a mechanics-first audit for investigation and hypothesis design, not clinical instruction.
Vagus Nerve Stimulation (VNS): electrical stimulation of vagal afferent/efferent fibers via:
Implanted VNS: surgical pulse generator + lead (typically cervical vagus).
Transcutaneous VNS (tVNS): noninvasive stimulation (commonly auricular branch targets; devices vary).
Indications (vary by region/approvals): refractory epilepsy, treatment-resistant depression; investigational in migraine, inflammatory conditions, PTSD, etc.
Mechanism (common clinical summary): stimulation modulates brainstem nuclei (e.g., NTS) → widespread neuromodulatory systems (LC norepinephrine, raphe serotonin, cholinergic pathways) → alters network excitability, mood regulation, seizure threshold, autonomic balance, inflammation.
Known reality: works well for some, modest for others; response predictors are incomplete; parameter space is large.
Target ambiguity: which fibers are actually being stimulated (afferent vs efferent; myelinated vs unmyelinated)?
Dose ambiguity: “mA, pulse width, frequency, duty cycle” are device-level proxies, not actual nerve recruitment.
Interface ambiguity: anatomy varies; electrode placement and tissue impedance vary; for tVNS, the actual vagal capture can be uncertain.
Outcome heterogeneity: delayed response in depression (months), variable in epilepsy; unclear mechanistic reason for timecourse differences.
Blinding / placebo complexity: stimulation sensations make sham controls hard; expectancy effects can confound.
Closed-loop absence (often): many protocols are open-loop despite state dependence likely being dominant.
VNS is a “control-input injection” into a high-leverage trunk line (vagus) that:
feeds brainstem gating hubs (NTS and connected nuclei),
shifts global system parameters: arousal gain, threat salience, seizure threshold, inflammatory tone, visceral prediction error,
and thereby changes which neural/behavioral “programs” (Somas) become default.
In IF terms:
Interface: nerve fibers + tissue impedance + electrode geometry
Control logic: periodic pulses = artificial “event markers” that bias gating/neuromodulator release
State effect: changes baseline selection weights in MC (what state becomes easy/hard to enter)
Key mechanical claim: VNS is less like “treating a symptom” and more like adjusting system gain and gating thresholds.
It stops being “mysterious neuromodulation” and becomes a parameterized gating protocol:
Hardware coupling layer: do you reliably recruit the intended fibers?
Control schedule layer: when/how often do you inject the control signal?
Network response layer: what the current brain/body state does with that signal.
Most variability likely sits in (1) and (3), while most clinical protocols tune (2) as if it’s primary.
Epilepsy improvements can appear earlier (threshold/gating effects).
Depression response often lags (plasticity + learning + state reweighting).
IF translation: some outcomes are “threshold shifts,” others are “retraining”.
Implanted VNS has more consistent coupling (usually).
tVNS may be a different intervention unless capture is verified.
IF insists: same label ≠ same mechanism unless coupling is proven.
Conventional explanation mixes many pathways and then calls it “complex.” IF reduces it to:
Coupling (what is stimulated, actually?)
Dose (nerve recruitment, not device settings)
Timing (state-dependent gating)
Outputs (what invariants shift?)
Without that decomposition, studies can’t compare apples-to-apples.
If the IF model is right, then:
“Non-responders” are often mis-coupled or wrong-state-timed, not inherently untreatable.
Reported efficacy will look inconsistent until protocols report:
coupling verification proxies,
baseline autonomic/network state,
and outcome domains aligned to expected mechanism (threshold shift vs retraining).
Also: You should not expect one universal parameter set. You should expect families of parameter regimes mapped to phenotypes.
A minimal “IF research bundle” for VNS would include:
Coupling verification proxies
evoked potentials (if feasible)
autonomic immediate responses (HRV shifts, pupillometry)
sensation maps (limited, but useful)
State typing
baseline HRV / baroreflex proxy
sleep/circadian disruption
EEG arousal markers (if available)
Outcome domain separation
fast outcomes (seizure threshold, arousal stability)
slow outcomes (mood durability, learning, rumination reduction)
State dependence
Same stimulation parameters will not produce the same outcome across different baseline autonomic/arousal states.
Prediction: outcomes improve when stimulation is timed to state (even crude timing).
Coupling dominates
Better coupling (consistent fiber recruitment) predicts better response more than “more mA.”
Prediction: once coupling is adequate, increasing intensity yields diminishing returns and more side effects.
Two outcome families
Some effects are immediate/threshold (seizure gating, arousal).
Some are delayed/retraining (mood).
Prediction: biomarkers differ by family; time-to-effect differs systematically.
Parameter regime families exist
There will be clusters: e.g., low-frequency long duty cycles vs higher-frequency shorter bursts mapping to different outcomes.
A) No state dependence
If controlling/timing for baseline state does not change outcomes, IF’s gating model weakens.
B) Coupling doesn’t matter
If verified coupling proxies do not correlate with response, “hardware coupling dominance” fails.
C) No regime clustering
If outcomes don’t cluster by parameter families (after controlling for coupling/state), the model needs revision.
D) Implanted and tVNS equivalence without coupling proof
If tVNS works identically across devices/placements without evidence of vagal capture, the “coupling-first” premise is wrong.
VNS is a control-signal injection into a trunk-line gating system. Variability is expected because:
coupling differs (what fibers are actually recruited),
baseline state differs (what the system does with the signal),
and outcomes differ in timescale (threshold shift vs retraining).
Does the work stand—does it obey the rules, does it violate the rules, or does it work?
Non-medical advice. This is a mechanics-first audit for investigation and hypothesis design, not clinical instruction.
Deep Brain Stimulation (DBS): surgically implanted electrodes deliver patterned electrical stimulation to specific brain targets, connected to an implanted pulse generator. In psychiatric use, targets vary (e.g., for OCD or depression), and protocols are still evolving.
DBS is established for movement disorders (e.g., Parkinson’s) with strong efficacy.
For psychiatric indications (OCD, depression, Tourette’s, etc.), evidence is promising but mixed; outcomes depend on target selection, patient selection, parameter tuning, and trial design.
Mechanism framing: stimulation modulates dysfunctional circuits (cortico-striato-thalamo-cortical loops; limbic/reward networks), altering activity patterns and symptoms.
What is the “dose”? Device parameters are not equivalent to neural recruitment; the activated volume and fiber pathways differ across individuals.
Target ambiguity: “Same target name” does not mean same tract engagement; millimeters matter.
Mechanism ambiguity: stimulation can inhibit, excite, desynchronize, or “jam” signals depending on context; simplistic inhibition/excitation stories fail.
Outcome heterogeneity: responders vs non-responders; delayed response in depression; variable in OCD.
Programming burden: parameter space is large; tuning is iterative and operator-dependent.
Trial challenges: sham controls, expectancy, and long time-to-effect complicate RCTs.
DBS is hardware-level insertion of a control node into an existing circuit loop.
In IF terms:
The disorder presentation is a stabilized pathological control regime (an attractor + policy loop).
DBS introduces a persistent control signal that reshapes the loop’s transfer function:
changes gain, thresholds, timing, and coupling between regions
alters which state programs become stable defaults
Key IF claim: psychiatric DBS is not “treating a symptom center.” It is re-parameterizing a loop (often via fiber tract engagement) so the system can exit a locked regime.
DBS outcomes depend less on the named nucleus and more on which white-matter pathways are modulated (connectomic framing).
IF translation: the effective target is a routing junction.
Immediate: changes in anxiety/arousal/compulsion intensity (threshold/gating).
Delayed: behavior reorganization, learning, mood stabilization (plasticity + habit loop rewiring).
IF translation: some effects are control gating, others are retraining.
The clinician is effectively doing black-box control tuning:
amplitude/pulse width/frequency = control inputs
symptom + side effects = outputs
network architecture is unknown but inferable
IF translation: DBS programming is manual adaptive control without full observability.
They map to adjacent tract recruitment and network spillover (mood elevation, apathy, impulsivity, hypomania, etc.).
IF translation: side effects are evidence of which pathways you’re actually hitting.
Psychiatric categories (depression, OCD) are broad labels. DBS operates on circuit topology, not labels. When studies group by diagnosis without topological typing, results appear inconsistent.
IF reduces it to four separable variables:
Topology engaged (tracts, connectivity)
State at stimulation (baseline arousal, comorbidity, meds)
Control regime (parameter family)
Outcome domain (acute gating vs slow relearning)
“Nonresponse” can be explained by:
wrong tract engagement (mis-target)
wrong parameter regime (wrong control law)
wrong phenotype (their pathology isn’t that loop)
The scalable advantage is not “better electrodes.” It’s better mapping + better control:
connectomic targeting
closed-loop or semi-closed-loop adaptation
outcome-domain-specific metrics
A minimal IF-aligned program for psychiatric DBS:
Use imaging/connectomics to predict which tract engagement pattern correlates with response.
Define “responders” by network signature, not diagnosis alone.
Model volume of tissue activated (VTA) and overlap with tracts.
Treat programming as exploration of parameter regimes with logging.
Separate:
fast outputs: anxiety intensity, compulsion urge threshold, affective lability
slow outputs: habit change, avoidance reduction, mood stability, functional capacity
Tract engagement predicts outcome better than named target.
Parameter families exist (distinct regimes produce distinct behavioral signatures).
Two timescales: immediate gating + delayed behavioral reorganization.
Side effects map to predictable tract spillover patterns.
State dependence: baseline arousal/medication shifts response to same settings.
A) If tract engagement measures do not predict response better than anatomy labels.
B) If parameter regimes do not cluster into reproducible families with distinct effects.
C) If there is no two-timescale pattern (no delayed learning component).
D) If side effects do not correlate with predicted pathway recruitment.
E) If stimulation works identically regardless of baseline state/med context.
Psychiatric DBS is loop re-parameterization via implanted control nodes. Its variability is expected because the true target is pathways, the system is state-dependent, and effects occur on multiple timescales. “Programming” is effectively control tuning without full observability—so better mapping and adaptive control should systematically improve results.
Does the work stand—does it obey the rules, does it violate the rules, or does it work?
Non-medical advice. This is a mechanics-first audit for investigation and hypothesis design, not clinical instruction.
FMT: transfer of processed stool from a screened donor to a recipient’s GI tract (via colonoscopy, enema, capsules, etc.) to alter the recipient’s gut microbial ecosystem.
Scope here: beyond recurrent C. difficile (where efficacy is strong and mechanism is comparatively clear: ecosystem replacement + colonization resistance).
Outside recurrent C. diff, FMT is investigated for IBD (UC/Crohn’s), IBS, metabolic conditions, neuropsychiatric associations, immune modulation, etc.
Results are variable and often trial-dependent.
Mechanism is framed as: “restore healthy microbiome diversity/function → modulate immune tone, barrier integrity, metabolite production, and gut-brain signaling.”
What is the ‘dose’? Is it number of organisms, species diversity, functional genes, metabolites, phage content, or colonization success?
Donor heterogeneity: “super-donors” appear in some studies; not reliably predictable.
Recipient state dominates: baseline microbiome, inflammation, antibiotics, diet, motility, bile acid pool, mucosal integrity.
Delivery route and schedule: capsules vs colonoscopic infusion; single vs repeated dosing; preconditioning varies.
Outcome definition drift: symptom scales vs endoscopic remission vs biomarkers vs quality of life.
Causality ambiguity: microbiome changes may be effect of improved disease state, not the cause.
FMT is an ecosystem re-seeding operation into a competitive, already-occupied habitat.
In IF terms:
Recipient gut = substrate + constraints (pH, bile acids, motility, mucus layer, immune activity, diet inputs).
Donor material = seed mixture (organisms + genes + metabolites + phage).
Therapeutic event = stable engraftment (long enough to shift system outputs), not mere exposure.
Key IF claim: FMT fails or varies mainly because it’s treated as “transfer X” instead of “engineer engraftment under constraints.”
Seeding (what you introduce)
Engraftment (does it take?)
Functional shift (do outputs change in the desired direction?)
Many trials measure (1) and assume (2); then are surprised when (3) is inconsistent.
The recipient environment can be:
receptive (cleared niches, supportive substrates)
resistant (niches occupied, hostile bile acids, immune activation)
IF translation: recipient has a colonization resistance architecture that must be managed.
Antibiotics, bowel lavage, diet changes, immunosuppression, flare status all change receptivity.
Repeated dosing may act less like “more treatment” and more like “increase probability of engraftment.”
Different conditions likely need different “functional outputs”:
IBD: barrier integrity + immune modulation
IBS: motility + visceral sensitivity + fermentation profiles
Metabolic: bile acid transformations + SCFA balance One donor profile may not satisfy all.
The term “microbiome diversity” is used as a stand-in for mechanism. IF forces decomposition into:
constraints (recipient environment)
control inputs (preconditioning, diet, delivery schedule)
measurable outputs (metabolites, inflammation markers, barrier function) Without that, trials compare non-equivalent protocols.
“Super-donor” may be a mislabel: the effect might be donor–recipient compatibility under specific constraints.
The scalable IP is not “stool delivery.” It is predicting and engineering engraftment:
recipient stratification
donor matching by function
defined consortia or metabolite-focused approaches
post-FMT substrate programming (diet + bile acid modulation)
A minimal IF-aligned study design would log, at minimum:
baseline microbiome composition + functional gene proxies
inflammation markers (CRP, fecal calprotectin if relevant)
bile acid profile (if available)
diet pattern
recent antibiotics and bowel prep
motility markers / stool form
not just taxonomy: metabolite production potential (SCFA, bile acid converters), phage load, antimicrobial resistance genes screening, etc.
longitudinal sampling (weeks to months)
quantify donor strain persistence (where feasible)
correlate with symptom/biomarker change
symptom relief vs biomarker change vs endoscopic/histologic improvement
Engraftment predicts outcome better than “dose given.”
Recipient receptivity (constraints) explains a large share of variance.
Repeated dosing improves outcomes mainly by increasing engraftment probability.
Donor-recipient matching outperforms “best donor for everyone.”
Function > taxonomy: metabolite/output shifts correlate more with benefit than species counts.
A) If stable engraftment does not correlate with clinical/biomarker benefit.
B) If recipient baseline constraints do not predict engraftment success.
C) If donor functional profiles do not matter (any screened donor works equally).
D) If repeated dosing does not increase engraftment probability or outcomes.
E) If metabolite/output changes don’t track benefit better than taxonomy.
Beyond C. diff, FMT is not a single intervention—it’s ecosystem engineering under constraints. Variability is expected because:
the true therapeutic event is engraftment + functional shift,
recipient environments differ dramatically,
and “microbiome improvement” must be defined by outputs relevant to the condition.
Does the work stand—does it obey the rules, does it violate the rules, or does it work?
Non-medical advice. This is a mechanics-first audit for investigation and hypothesis design, not clinical instruction.
Ketamine infusion therapy: controlled administration of ketamine (usually IV; sometimes IM/oral variants exist) in monitored sessions, used for:
rapid reduction of depressive symptoms (incl. suicidality) in some patients
chronic pain syndromes in some protocols
Depression: ketamine can produce rapid antidepressant effects (hours to days) in a subset; durability varies.
Pain: ketamine is used as an analgesic and anti-hyperalgesic in some chronic pain conditions.
Mechanism narratives (often blended):
NMDA receptor antagonism → glutamate surge → AMPA activation → synaptogenesis/plasticity (BDNF/mTOR pathways)
network connectivity changes (default mode, salience)
anti-inflammatory effects (context-dependent)
dissociation correlates with response in some studies, but not always
What is the therapeutic event? pharmacologic receptor action vs subjective dissociative state vs the post-session plasticity window.
Dose vs experience ambiguity: same mg/kg can yield different subjective and physiologic states across people.
Setting dependence: “set and setting” influences outcomes, but is treated inconsistently across clinics.
Durability problem: rapid improvement often fades without continuation/maintenance; mechanisms for relapse unclear.
Responder prediction: biomarkers and phenotypes that predict durable response are weak.
Pain vs depression protocols diverge: suggests multiple mechanisms and timescales.
Ketamine infusion is a state-shift injection that creates:
an acute state transition (altered perception, salience, self-model loosened to varying degrees),
followed by a reorganization/plasticity window, during which default patterns can reweight.
In IF terms:
Input: ketamine dose + infusion curve + environment (sensory/social constraints)
State transition: temporary loosening of rigid predictive loops (“stuck” programs)
Window: heightened plasticity + altered affective gating
Output: short-term symptom relief; long-term change depends on consolidation
Key IF claim: ketamine’s variability is largely explained by (a) state depth, (b) container quality, and (c) consolidation protocol, not dose alone.
Pharmacologic perturbation (receptor-level)
Phenomenological state (what the person’s MC is running during/after)
Consolidation mechanics (what stabilizes afterward)
Most clinics treat (1) as the whole procedure. IF treats (2) and (3) as co-equal.
Fast: relief via gating changes (hours–days)
Slow: durable change via learning and reweighting (weeks–months)
IF translation: ketamine can “unlock” a stuck state quickly, but durability requires post-unlock re-training.
Instead of “dissociation is necessary / not necessary,” IF asks:
which state depth is required for which phenotype?
can equivalent state depth be achieved with different subjective labeling?
do responders show a consistent state signature (physio + cognitive markers), even if they don’t report it similarly?
Chronic pain may involve:
central sensitization loops
threat/prediction error loops
affective amplification Ketamine may break different links in different patients.
Ketamine got framed as either:
purely biochemical (NMDA story), or
purely experiential (“psychedelic therapy”-adjacent)
IF reduction: it is a perturbation + window protocol. Both biochemical and experiential variables can be treated as control knobs that shape reorganization.
Clinics that only “administer dose” will show high variance and weak durability.
Competitive advantage likely comes from:
state characterization (what state was actually induced?)
container standardization (environmental constraints)
consolidation protocol (post-session behavioral/learning scaffolding)
phenotype matching (who needs deeper vs lighter state shifts)
This is explainability without needing to claim mystical mechanisms.
Potential measurement domains (clinic-feasible):
dissociation scales (CADSS), but also
autonomic markers (HRV), pupil response
simple cognitive flexibility tasks pre/post
sleep architecture changes post-session
sensory load (sound, light)
social interaction level
narrative input (what is said during/after)
time for recovery and reorientation
Track:
24–48h symptom shift
2–4 week retention
functional metrics (work, sleep, pain interference)
If ketamine opens a window but the system drifts back, maintenance isn’t a failure—it’s a state-locking requirement until new weights stabilize.
State depth correlates with acute response (not perfectly with dose).
Container quality correlates with durability (post-session stabilization).
Two-timescale pattern: fast relief vs slower consolidation.
Responder phenotypes exist (some require deeper state shifts; others respond to lighter).
Relapse corresponds to re-formation of prior loops without consolidation.
A) If induced state measures (phenomenology/physio) do not correlate with outcomes at all.
B) If container variables (setting, post-session protocol) have zero effect on durability in controlled trials.
C) If durable change occurs consistently without any consolidation differences (dose alone predicts durability).
D) If there is no identifiable two-timescale pattern (acute vs durable outcomes behave the same).
Ketamine infusion is best modeled as a state-transition + plasticity-window protocol. Dose starts the process, but variability and durability are dominated by:
what state was actually achieved,
how the environment constrained that state,
and what consolidation mechanics followed.
Does the work stand—does it obey the rules, does it violate the rules, or does it work?
Non-medical advice. This is a mechanics-first audit for investigation and hypothesis design, not clinical instruction.
Spinal Cord Stimulation (SCS): implanted electrodes (typically epidural) deliver patterned electrical stimulation to dorsal column/dorsal horn pathways, aiming to reduce chronic pain perception and improve function. Systems may be:
paresthesia-based (traditional tonic)
paresthesia-free (e.g., high-frequency, burst, other waveforms)
sometimes with sensing/closed-loop features (varies by device)
Indications: neuropathic pain syndromes (e.g., failed back surgery syndrome), CRPS, peripheral neuropathies, etc.
Mechanism framing:
“gate control” theory (stimulate large fibers → inhibit pain transmission)
modulation of dorsal horn circuits
supraspinal effects (descending inhibition, cortical network changes)
Reality: meaningful benefit for some; non-response and tolerance for others; mechanisms depend on waveform and phenotype.
True dose is unknown: device amplitude ≠ neural recruitment; depends on lead position, CSF thickness, posture, tissue impedance.
Target ambiguity: SCS is positioned in spinal levels, but the effective circuit engagement includes dorsal horn interneurons and ascending pathways.
Waveform plurality: tonic vs burst vs high-frequency likely engage different circuits; “SCS” isn’t one mechanism.
Outcome heterogeneity: pain scores vs function vs sleep vs opioid reduction can move independently.
Tolerance/adaptation: some patients lose benefit over time; unclear whether neural adaptation, disease progression, or parameter mismatch dominates.
Psychosocial/behavioral coupling: pain is not only sensory; threat, attention, and prediction loops alter perception.
SCS is control-signal injection into a sensory gating pipeline.
In IF terms:
Chronic pain (often) = a stabilized error-regime: persistent threat prediction + sensitized signal amplification + attention capture.
SCS introduces patterned stimulation that:
alters gain and timing of nociceptive transmission,
modifies local spinal processing,
and can secondarily shift supraspinal interpretations (salience/threat).
Key IF claim: SCS is a feedback control intervention; success depends on matching the stimulation regime to the individual’s pain architecture (sensory vs affective vs prediction-dominant).
Coupling layer: are you recruiting the intended fibers consistently across posture and day?
Control regime layer: waveform family (tonic/burst/high-frequency) = different control laws.
Interpretation layer: what the brain does with altered input (threat, attention, learning).
A lot of “non-response” is failure in (1) or mismatch in (2), while durability often depends on (3).
Clinicians tune parameters against outputs (pain relief, paresthesia, function). That is manual adaptive control with partial observability.
Lead-to-cord distance changes with posture → stimulation field changes → apparent inconsistent efficacy.
IF translation: unmodeled geometry changes = unmodeled dose changes.
If paresthesia-free waveforms work, the mechanism cannot be reduced to “replace pain with tingling.” It implies deeper circuit modulation or timing/gain changes.
SCS is often discussed as a device therapy with “parameters,” but without a clean model of:
what constitutes adequate coupling,
which waveform family matches which pain phenotype,
and which outcome domain is being optimized.
IF reduces the apparent mystery to control + coupling + phenotype.
Competitive advantage is less “more parameters” and more:
phenotype typing (what kind of pain architecture is this?)
robust coupling (closed-loop amplitude adjustment, posture compensation)
regime libraries (waveform families matched to phenotypes)
multi-domain outcomes (function/sleep/attention, not pain score only)
SCS success is expected to improve with better sensing and closed-loop control.
Track separately:
sensory pain intensity
pain interference (function)
sleep continuity
attention capture / catastrophizing proxies
opioid use (if relevant)
Log posture and stimulation amplitude requirements; consider devices or protocols that adjust automatically.
Even simple stratification:
neuropathic vs nociplastic features
allodynia/hyperalgesia presence
affective threat dominance (fear avoidance)
CRPS-like autonomic changes
Some benefits are immediate gating; durable benefit may require behavior/attention retraining once pain is reduced.
Coupling consistency predicts response (better than raw amplitude).
Waveform families cluster by phenotype and outcome domain.
Posture dependence explains variance unless compensated.
Two-timescale effects: immediate gating vs slower recalibration (learning).
Function can improve without pain score matching (different outputs shift).
A) If coupling metrics (e.g., posture-linked amplitude changes) do not relate to efficacy.
B) If waveform family choice does not matter after controlling for coupling.
C) If phenotype typing does not improve prediction of responders.
D) If there is no two-timescale pattern (no learning/retuning component).
E) If closed-loop compensation provides no improvement over open-loop.
SCS is best modeled as sensory gating + feedback control. Variability is expected because:
the true dose changes with geometry/posture,
different waveforms implement different control laws,
and chronic pain includes both signal and interpretation loops.
Does the work stand—does it obey the rules, does it violate the rules, or does it work?
This is a mechanics-first governance tool: it exposes what a guideline is assuming, what it actually knows, where it generalizes, and what would force revision. It’s useful because most guideline conflicts come from hidden premises, not data.
Assumption Ledger (AL-1): a table of every assumption the guideline relies on
Boundary Map (BM-1): where the guideline applies / does not apply
Evidence Coupling Map (ECM-1): which recommendations depend on which evidence and which assumptions
Falsifier Set (FS-1): what findings would overturn each assumption/recommendation
Drift Monitor (DM-1): what to track over time to know the guideline is aging out
Turn narrative into atomic statements:
“Do X for Y in population Z under conditions C, because mechanism M / evidence E.”
Every “should” becomes a row.
IF extraction categories (use these headers):
Population assumptions (who is being treated; what is “normal”)
Mechanism assumptions (why X should affect Y)
Coupling assumptions (does X actually interface with target tissue/system?)
Dose/control assumptions (is dose defined by device setting or by physiological effect?)
State assumptions (baseline state matters or not?)
Outcome assumptions (what counts as success; timescale)
Risk assumptions (what harms are expected/acceptable)
Implementation assumptions (operator skill, equipment, adherence)
Generalization assumptions (trial setting → real world)
Each assumption gets a status:
MEASURED (directly measured in relevant context)
INFERRED (reasonable but not directly measured)
CONTESTED (credible disagreement exists)
UNKNOWN (not established)
OUTDATED_RISK (likely invalid due to new tech/practice)
For each assumption:
Boundary: “This holds only if ____”
Falsifier: “This fails if we observe ____”
Replacement path: “If falsified, update recommendation by ____”
Each recommendation should list:
evidence sources (study types)
required assumptions (IDs)
the “weakest link” assumption (highest uncertainty + highest impact)
That’s how you stop argument loops.
Use low | medium | high confidence bands like your SOMA system.
AL-1 ASSUMPTION LEDGERAssumption ID:Guideline Claim ID(s):Assumption Statement (atomic, testable):Type: [Population | Mechanism | Coupling | Dose/Control | State | Outcome | Risk | Implementation | Generalization]Status: [MEASURED | INFERRED | CONTESTED | UNKNOWN | OUTDATED_RISK]Confidence Band: [low | medium | high]Evidence Basis: [RCT | Observational | Meta-analysis | Mechanistic | Expert consensus | Device data | Registry]Boundary Conditions (where it holds):Disconfirmers / Falsifiers (what breaks it):Impact if Wrong: [low | medium | high]Mitigation / Update Rule (what changes in the guideline if falsified):Notes / Links:
When guideline language is vague, run these reductions:
Replace “effective” with measured endpoint + time horizon
e.g., “reduces pain” → “reduces pain interference score by X at 12 weeks”
Replace “dose” with physiological dose when possible
device setting ≠ recruitment ≠ tissue effect
if physiological dose is unknown, explicitly mark it as a top assumption.
Split outcomes by timescale
acute response vs durable response vs relapse
Separate coupling failure from treatment failure
if the interface didn’t engage, you cannot conclude non-efficacy.
Never collapse heterogeneous populations
stratify or state a boundary.
(generic neuromodulation-style example—swap to ECT/VNS/DBS/SCS when you choose your guideline)
Claim C-01: “Use intervention X for condition Y after 2 failed meds.”
Assumptions:
A-01 (Population): “Y is a single treatable architecture.”
Status: CONTESTED, Confidence: low
Falsifier: outcomes cluster into distinct phenotypes with opposite responses
A-02 (Coupling): “Device setting reliably recruits target fibers.”
Status: INFERRED, Confidence: medium
Falsifier: coupling proxy does not correlate with symptom change
A-03 (Outcome): “Primary outcome at 6 weeks predicts durability.”
Status: UNKNOWN, Confidence: low
Falsifier: early responders relapse at same rate as non-responders
Update rule:
If A-02 fails → guideline must require coupling verification proxy reporting.
If A-01 fails → guideline must require phenotype stratification before recommending X.
This is how IF makes a guideline upgradeable instead of ideological.
Does the work stand—does it obey the rules, does it violate the rules, or does it work?
This is the simplest IF upgrade that immediately reduces variance and makes outcomes explainable—without changing the core intervention.
Question: Did the intervention actually engage the intended substrate in this specific patient, this specific session?
Output: Coupling = pass | weak | fail
If coupling fails, you cannot interpret outcome (it’s a delivery failure, not a therapy failure).
Examples of coupling proxies (by procedure)
ECT: EEG-confirmed seizure + seizure quality marker (not just duration)
VNS/tVNS: reproducible autonomic/evoked proxy suggesting vagal capture
DBS/SCS: lead position/field estimate + side-effect map consistent with intended tract recruitment; posture sensitivity logged
FMT: engraftment evidence over time (donor strain persistence / functional shift), not “dose delivered”
Ketamine: state-depth signature (phenomenology + physiologic markers), not mg/kg alone
Question: What regime family did we apply, and is it the right one for this phenotype?
Output: Regime family = R1…Rn (small library)
This is where you stop pretending every parameter combination is unique. You define a few control laws.
Examples
ECT: unilateral ultra-brief low multiple vs bilateral higher multiple (regime families)
VNS: intermittent vs continuous duty; low vs high frequency families
DBS: high-frequency “jamming” style vs lower-frequency modulation families (conceptually)
SCS: tonic vs burst vs high-frequency families
FMT: single-dose vs repeated-dose + preconditioning families
Ketamine: infusion curve + session cadence families
Question: After the perturbation, what stabilizes the system so it doesn’t drift back?
Output: Consolidation = present | partial | absent
This stage is why many interventions look “mysteriously temporary.”
What consolidation looks like (generic)
standardized post-session environment (“container”)
sleep/circadian protection
behavioral scaffolding during plasticity window
maintenance schedule based on drift signals (not just symptom collapse)
No coupling → no conclusion. Fix coupling first.
Coupling ok + no response → wrong regime or wrong phenotype. Adjust regime family before abandoning.
Fast response but poor durability → consolidation failure. Build maintenance/container.
Durable response → lock the recipe. That becomes the phenotype–regime match.
This is the mechanical core.
CASE PROTOCOL (3-STAGE)Stage 1: Coupling- Intended substrate:- Coupling proxies used:- Result: pass | weak | fail- Notes (why):Stage 2: Control Regime- Regime family (R#):- Key parameters (only the ones that matter):- Rationale for this phenotype:Stage 3: Consolidation- Post-window protocol used:- Maintenance plan / drift signals:- Result: present | partial | absentOutcomes- Fast outcome (0–72h):- Slow outcome (2–8w):- Adverse effects:
Non-medical advice. This is an investigation/standardization framework to reduce variance and make outcomes interpretable. Clinical decisions must remain with qualified clinicians.
Therapeutic event (ECT): an adequate generalized seizure with sufficient network engagement.
EEG seizure present (yes/no) + seizure duration (coarse)
Seizure quality marker(s) (strongly recommended)
e.g., post‑ictal suppression depth, coherence/spread proxies, morphology indices (whatever your system uses)
Physiologic confirmation
autonomic response patterns (HR/BP changes) and recovery profile (supporting, not primary)
Coupling result (banded)
pass: seizure achieved + quality marker meets threshold
weak: seizure achieved but quality borderline / inconsistent
fail: no seizure or abort/insufficient engagement
IF rule: If coupling = fail, outcome data cannot be used to judge efficacy—log as delivery failure.
ECT “dose” is not just mC; it’s a regime family defined by:
electrode placement (RUL / BL / BF)
pulse width (ultra‑brief vs brief)
charge relative to threshold (× seizure threshold)
session cadence
You can keep it tight:
R1: RUL + ultra‑brief + low‑multiple
Goal: maximize cognitive safety; first-line where feasible
R2: RUL + brief + moderate‑multiple
Goal: stronger perturbation with still-lower cognitive cost than bilateral
R3: BF + brief + moderate‑multiple
Goal: broaden network engagement while managing memory risk (intermediate)
R4: BL + brief + lower‑to‑moderate multiple
Goal: faster/stronger response when severity demands
R5: BL + brief + higher multiple (rescue)
Goal: refractory cases; highest side‑effect risk
IF rule: Do not treat “nonresponse” as final until you’ve verified:
Coupling was consistently pass, and
at least one regime shift (e.g., R1→R2 or R2→R4) was attempted under a logged rationale.
ECT has a built‑in destabilization cost: you’re forcing a reset. Consolidation is the re-stabilization strategy.
Post‑session stabilization window (same day)
protect sleep opportunity; minimize chaotic sensory load; consistent reorientation routine
Between‑session drift control (days–weeks)
monitor early drift signals (sleep fragmentation, agitation/retardation, rumination intensity, function)
Maintenance logic (weeks–months, if needed)
maintenance ECT or other stabilization plan triggered by drift signals, not only full relapse
IF rule: If you see fast+ response with slow- durability, do not label it “partial responder” until consolidation is upgraded; label it fragile responder (consolidation-limited).
Track two timescales explicitly:
Fast (0–72h): suicidality, psychomotor retardation, agitation, mood score delta
Slow (2–8w): functional capacity, relapse interval, sustained remission, cognition trajectory
Coupling fail → fix coupling / threshold / anesthesia interference / measurement; don’t interpret outcome
Coupling pass + no response → change regime family (RUL→BF/BL, pulse width, multiple)
Response + heavy cognitive cost → downshift regime (BL→BF/RUL, brief→ultra‑brief, lower multiple) once stable
Fast response but relapse → upgrade consolidation + maintenance triggers
pass / weak / fail)Coupling = did we induce an adequate seizure with sufficient network engagement?
Pass
EEG seizure achieved and
seizure quality marker(s) meet threshold (your chosen index) and
recovery profile not grossly abnormal for the dose
Weak
EEG seizure achieved but quality marker borderline/inconsistent or
large session-to-session variance (same nominal regime, different seizure quality)
Fail
no seizure / aborted / clearly inadequate engagement
Rule: Fail = delivery failure (do not count as non-response). Weak = treat as “coupling-limited”—either fix coupling or increase regime before judging efficacy.
Use the regime library exactly as provided (R1 RUL ultra-brief low multiple → R5 BL high multiple rescue) and require a regime label on every session.
Standardize:
post-session stabilization window
drift signals between sessions
maintenance triggers
Coupling: pass/weak/fail | Regime: R# | Outcome: fast+/fast-; slow+/slow- | Cognition: ok/impacted | Next: fix coupling / shift regime / add consolidation
Does the work stand—does it obey the rules, does it violate the rules, or does it work?
If your work touches incentives, flows, decision-making, market design, or systemic risk, you’re already standing inside this map.
For collaboration, critique, or formal debate:
leadauditor@mc-sa-if.com